JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 30, 2025, titled "Press Release".
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Chemicals & Pharmaceuticals reported Q1 FY26 revenue of INR 1,094 crores, up 9% from INR 1,004 crores in Q1 FY25. Operating EBITDA grew 13% to INR 330 crores, with margins expanding to 30.2% (from 29.0%), crossing the 30% mark for the first time. Net Profit rose 14% to INR 202 crores. Domestic formulations led the show with 14% growth to INR 678 crores, while international formulations grew marginally by 2% to INR 416 crores. The CDMO business posted 8% growth to INR 115 crores, and gross margins improved to 68.3% from 66.2%. Results included one-off charges linked to a proposed merger scheme.
Strong, broad-based quarterly performance with margin expansion and double-digit profit growth is positive for shareholders. The company's ability to grow faster than the Indian pharma market (13% vs IPM's 9%) and hit a 30%+ EBITDA margin milestone signals improving operational quality, likely to be viewed favorably by the market.